Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

NCT06584032 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

412

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Endometrial Cancer

Interventions

DRUG: fruquintinib
BIOLOGICAL: sintilimab
DRUG: paclitaxel
DRUG: doxorubicin

Sponsor

Hutchmed